NCT04448964

A Study of JNJ-70033093 in Healthy Participants

A Randomized, Open-Label, 3-way Cross-over (Part 1) and 2-way Cross-over (Part 2) Study in Healthy Participants to Evaluate the Relative Bioavailability and the Food Effect of an Oral Tablet Formulation Relative to a Capsule Formulation of JNJ-70033093

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of a single dose of JNJ-70033093 spray dried dispersion (SDD) tablets compared with JNJ-70033093 SDD granule capsules in healthy participants under fasting conditions in Part 1 and 2 and to assess the effect of food on the bioavailability of a single dose of JNJ-70033093 SDD tablets in Part 1.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-70033093	JNJ-70033093 will be administered orally as per assigned treatment sequence.

Timeline

• Start date: 2020-06-26
• Primary completion: 2020-11-14
• Completion: 2020-11-14
• First posted: 2020-06-26
• Last updated: 2025-03-30

Locations

1 site across 1 country: Belgium

Regulatory

• FDA-regulated drug study